Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04875884 · ClinicalTrials.gov registry record · NA

Optimized MRI of Patients With Hip Arthroplasty

A NA study of Hip Arthropathy, sponsored by NYU Langone Health.

Recruiting
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT04875884: Recruiting NA study of Hip Arthropathy, sponsored by NYU Langone Health.

NCT04875884 is a NA study of Hip Arthropathy that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 22 participants, below the 58-participant average among 4 other Hip Arthropathy trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04875884, a NA study of Hip Arthropathy, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

This is a single-center single-arm clinical trial with a paired design which compares the effectiveness of 3T MRI with (modified) and without (standard) radiofrequency pulse polarization optimization in reducing metal-related artifacts in patients with hip arthroplasty implants.

Primary Outcome

The area of artifact degraded regions (in pixel\^2) in paired images of modified and standard MRIs determined by manual segmentation.

Conditions Studied

Interventions

  • DEVICE Modified MRI

Study Locations (1)

New York

  • NYU Langone Radiology - Center for Biomedical Imaging - New York

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2022-08-11
Est. Completion 2027-12-30
Phase NA
NYU Langone Health

1,164 total trials

What NCT04875884 shows while recruiting

NCT04875884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 58-participant average among 4 other Hip Arthropathy trials with a reported enrollment target (62% lower).

The record links to 1 condition, with Hip Arthropathy appearing as the primary indexed condition, and to 1 intervention - of which Modified MRI is the first listed.

NCT04875884 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04875884 about?

NCT04875884 is a clinical study titled "Optimized MRI of Patients With Hip Arthroplasty". This is a single-center single-arm clinical trial with a paired design which compares the effectiveness of 3T MRI with (modified) and without (standard) radiofrequency pulse polarization optimization in reducing metal-related artifacts in patients with hip arthroplasty implants.

What is the current status of trial NCT04875884?

This trial is currently recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2022-08-11. Estimated completion is 2027-12-30.

What conditions does trial NCT04875884 study?

This clinical trial studies the following conditions: Hip Arthropathy.

What interventions are being tested in trial NCT04875884?

The interventions under investigation include: Modified MRI (DEVICE).

Who is sponsoring clinical trial NCT04875884?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04875884 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hip Arthropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04875884, the US trial registry maintained by the National Library of Medicine. NCT04875884 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.